Becton, Dickinson and Company (NYSE:BDX) Expected to Announce Quarterly Sales of $4.86 Billion

Wall Street analysts expect Becton, Dickinson and Company (NYSE:BDXGet Rating) to announce $4.86 billion in sales for the current fiscal quarter, according to Zacks. Nine analysts have made estimates for Becton, Dickinson and’s earnings, with the lowest sales estimate coming in at $4.77 billion and the highest estimate coming in at $4.92 billion. Becton, Dickinson and posted sales of $4.91 billion in the same quarter last year, which suggests a negative year-over-year growth rate of 1%. The firm is expected to issue its next earnings results before the market opens on Monday, January 1st.

On average, analysts expect that Becton, Dickinson and will report full-year sales of $19.58 billion for the current financial year, with estimates ranging from $19.14 billion to $19.71 billion. For the next year, analysts forecast that the business will report sales of $20.44 billion, with estimates ranging from $19.60 billion to $20.66 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Becton, Dickinson and.

Becton, Dickinson and (NYSE:BDXGet Rating) last posted its earnings results on Thursday, February 3rd. The medical instruments supplier reported $3.64 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.86 by $0.78. Becton, Dickinson and had a net margin of 8.75% and a return on equity of 14.87%. The firm had revenue of $5 billion for the quarter, compared to analysts’ expectations of $4.76 billion. During the same quarter last year, the firm earned $4.55 EPS. The company’s quarterly revenue was down 6.0% compared to the same quarter last year.

A number of research analysts recently weighed in on BDX shares. Bank of America started coverage on shares of Becton, Dickinson and in a research note on Tuesday, March 1st. They issued a “neutral” rating for the company. Morgan Stanley upped their target price on Becton, Dickinson and from $293.00 to $295.00 and gave the stock an “overweight” rating in a research note on Monday, April 11th. SVB Leerink raised their price target on Becton, Dickinson and from $270.00 to $275.00 and gave the company a “market perform” rating in a report on Friday, February 4th. Wells Fargo & Company raised their price target on Becton, Dickinson and from $275.00 to $285.00 and gave the company an “equal weight” rating in a report on Friday, April 1st. Finally, StockNews.com assumed coverage on Becton, Dickinson and in a report on Thursday, March 31st. They issued a “buy” rating on the stock. Six research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $276.25.

Shares of NYSE:BDX traded up $0.74 during mid-day trading on Monday, reaching $271.68. The company had a trading volume of 921,740 shares, compared to its average volume of 1,139,417. The company has a current ratio of 1.23, a quick ratio of 0.78 and a debt-to-equity ratio of 0.68. The firm has a market cap of $77.37 billion, a price-to-earnings ratio of 47.00, a PEG ratio of 3.34 and a beta of 0.65. The company’s 50-day moving average price is $267.42 and its 200-day moving average price is $255.67. Becton, Dickinson and has a one year low of $235.13 and a one year high of $280.62.

The business also recently declared a quarterly dividend, which was paid on Thursday, March 31st. Investors of record on Thursday, March 10th were given a dividend of $0.87 per share. The ex-dividend date was Wednesday, March 9th. This represents a $3.48 annualized dividend and a yield of 1.28%. Becton, Dickinson and’s payout ratio is 60.21%.

In other news, EVP Alexandre Conroy sold 6,410 shares of Becton, Dickinson and stock in a transaction that occurred on Thursday, February 3rd. The stock was sold at an average price of $270.16, for a total value of $1,731,725.60. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Betty D. Larson sold 14,374 shares of Becton, Dickinson and stock in a transaction that occurred on Friday, February 25th. The stock was sold at an average price of $271.90, for a total value of $3,908,290.60. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,625 shares of company stock worth $5,868,516. 0.50% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. TD Asset Management Inc. raised its stake in Becton, Dickinson and by 1.7% during the third quarter. TD Asset Management Inc. now owns 214,740 shares of the medical instruments supplier’s stock valued at $52,787,000 after buying an additional 3,486 shares during the last quarter. Magnolia Capital Management Ltd. purchased a new position in Becton, Dickinson and during the fourth quarter valued at $55,000. NTV Asset Management LLC raised its stake in Becton, Dickinson and by 11.3% during the third quarter. NTV Asset Management LLC now owns 6,494 shares of the medical instruments supplier’s stock valued at $1,596,000 after buying an additional 661 shares during the last quarter. FIL Ltd raised its stake in Becton, Dickinson and by 174.6% during the third quarter. FIL Ltd now owns 340,420 shares of the medical instruments supplier’s stock valued at $83,682,000 after buying an additional 216,440 shares during the last quarter. Finally, Pinebridge Investments L.P. raised its stake in Becton, Dickinson and by 6.8% during the third quarter. Pinebridge Investments L.P. now owns 42,022 shares of the medical instruments supplier’s stock valued at $10,330,000 after buying an additional 2,676 shares during the last quarter. Institutional investors own 84.66% of the company’s stock.

About Becton, Dickinson and (Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Featured Articles

Get a free copy of the Zacks research report on Becton, Dickinson and (BDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.